Arcturus Therapeutics Holdings Inc. $ARCT Shares Sold by Woodline Partners LP

Key Points

• Woodline Partners LP has reduced its stake in Arcturus Therapeutics by 3.3%, now holding 780,442 shares valued at approximately $8.27 million.
• Several institutional investors have increased their holdings, with GAMMA Investing LLC raising its position by 3,482.9% in the first quarter.
• Arcturus Therapeutics reported quarterly earnings showing a significant revenue of $28.30 million, surpassing analyst expectations, and had a consensus rating of "Buy" with an average target price of $50.57.

Woodline Partners LP lessened its position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) by 3.3% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 780,442 shares of the biotechnology company's stock after selling 26,470 shares during the period. Woodline Partners LP owned about 2.88% of Arcturus Therapeutics worth $8,265,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Deutsche Bank AG raised its position in shares of Arcturus Therapeutics by 42.7% in the fourth quarter. Deutsche Bank AG now owns 24,768 shares of the biotechnology company's stock valued at $420,000 after buying an additional 7,417 shares during the last quarter. Invesco Ltd. raised its position in shares of Arcturus Therapeutics by 83.1% in the first quarter. Invesco Ltd. now owns 34,896 shares of the biotechnology company's stock valued at $370,000 after buying an additional 15,836 shares during the last quarter. Y Intercept Hong Kong Ltd acquired a new position in Arcturus Therapeutics during the first quarter worth approximately $244,000. GAMMA Investing LLC increased its position in Arcturus Therapeutics by 3,482.9% during the first quarter. GAMMA Investing LLC now owns 5,231 shares of the biotechnology company's stock worth $550,000 after purchasing an additional 5,085 shares during the last quarter. Finally, Ameriprise Financial Inc. increased its position in Arcturus Therapeutics by 5.0% during the fourth quarter. Ameriprise Financial Inc. now owns 18,613 shares of the biotechnology company's stock worth $316,000 after purchasing an additional 883 shares during the last quarter. Institutional investors and hedge funds own 94.54% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on ARCT shares. Leerink Partners dropped their price objective on shares of Arcturus Therapeutics from $63.00 to $54.00 and set an "outperform" rating for the company in a research report on Friday, August 22nd. Wall Street Zen raised shares of Arcturus Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, August 9th. Scotiabank reissued an "outperform" rating on shares of Arcturus Therapeutics in a research report on Wednesday, July 2nd. HC Wainwright started coverage on shares of Arcturus Therapeutics in a research report on Thursday, September 4th. They issued a "buy" rating and a $60.00 price objective for the company. Finally, Citigroup reissued a "buy" rating and issued a $49.00 price objective (up previously from $47.00) on shares of Arcturus Therapeutics in a research report on Tuesday, August 12th. Eight analysts have rated the stock with a Buy rating, According to MarketBeat.com, Arcturus Therapeutics presently has a consensus rating of "Buy" and an average target price of $50.57.

Arcturus Therapeutics Trading Up 0.3%

ARCT opened at $18.04 on Friday. The company has a fifty day simple moving average of $15.30 and a 200 day simple moving average of $13.41. The firm has a market cap of $489.88 million, a price-to-earnings ratio of -8.09 and a beta of 2.39. Arcturus Therapeutics Holdings Inc. has a twelve month low of $8.04 and a twelve month high of $25.88.

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last released its quarterly earnings results on Monday, August 11th. The biotechnology company reported ($0.34) earnings per share for the quarter, beating analysts' consensus estimates of ($1.11) by $0.77. The business had revenue of $28.30 million during the quarter, compared to analyst estimates of $17.64 million. Arcturus Therapeutics had a negative net margin of 49.26% and a negative return on equity of 24.87%. On average, analysts forecast that Arcturus Therapeutics Holdings Inc. will post -2.22 earnings per share for the current fiscal year.

Arcturus Therapeutics Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.

Want to see what other hedge funds are holding ARCT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.